Published in J Psychiatr Res on November 26, 2007
Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry (2014) 3.28
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol (2009) 2.33
The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov (2013) 2.00
Antidepressants versus placebo in major depression: an overview. World Psychiatry (2015) 1.56
A model of placebo response in antidepressant clinical trials. Am J Psychiatry (2013) 1.46
A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci (2009) 0.93
Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis. PLoS One (2015) 0.82
Vagal Nerve Stimulation for Treatment-Resistant Depression. Neurotherapeutics (2017) 0.80
Understanding the non-pharmacological correlates of self-reported efficacy of antidepressants. Acta Psychiatr Scand (2015) 0.77
Antidepressant or antidepressant plus placebo effect? World Psychiatry (2015) 0.76
Placebo treatment in mild to moderate depression. Br J Gen Pract (2011) 0.75
Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol (2002) 3.58
Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry (2003) 3.50
Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry (2013) 2.76
Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder. Am J Psychiatry (2010) 1.82
A systematic review of comparative efficacy of treatments and controls for depression. PLoS One (2012) 1.57
Addressing psychotherapy challenges in the medication visit: a pilot course on brief psychotherapeutic interventions. Acad Psychiatry (2014) 1.39
Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res (2005) 1.13
Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol (2002) 1.11
Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. J Affect Disord (2002) 1.05
Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol (2005) 1.04
Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs (2009) 1.02
BMI, sex, and antidepressant response. J Affect Disord (2006) 0.93
Neural and endocrine correlates of sadness in women: implications for neural network regulation of HPA activity. J Neuropsychiatry Clin Neurosci (2004) 0.92
Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports. Neuropsychopharmacology (2007) 0.91
Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig (2007) 0.91
Are patients with depression at heightened risk of suicide as they begin to recover? Psychiatr Serv (2009) 0.84
Antidepressant-placebo differences in 16 clinical trials over 10 years at a single site: role of baseline severity. Psychopharmacology (Berl) (2010) 0.81
Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. J Clin Psychiatry (2007) 0.79
Magnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interviews (SIGMA-RAPS) compared to trials using traditional semi-structured interviews. Psychopharmacology (Berl) (2014) 0.79
Efficacy and safety of anti-manic agents in children and adults. Isr J Psychiatry Relat Sci (2012) 0.75
A correction. Arch Gen Psychiatry (2002) 0.75
Suicide risk analysis among patients assigned to psychotropics and placebo. Psychopharmacol Bull (2006) 0.75
Are the colors and shapes of current psychotropics designed to maximize the placebo response? Psychopharmacology (Berl) (2010) 0.75
Is "medication visit" a misnomer? Psychotherapy challenges in 90862. Psychiatr Serv (2011) 0.75